$10.62
3.01% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US00211Y4070
Symbol
ORKA
Sector
Industry

ARCA biopharma, Inc. Stock price

$10.62
+1.32 14.19% 1M
-11.58 52.16% 6M
-8.77 45.23% YTD
-10.42 49.52% 1Y
-4.35 29.07% 3Y
-13.78 56.47% 5Y
-644.08 98.38% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.31 3.01%
ISIN
US00211Y4070
Symbol
ORKA
Sector
Industry

Key metrics

Market capitalization $397.62m
Enterprise Value $52.41m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.10
Dividend yield 0.00%
Last dividend (FY24) $19.36
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-87.61m
Free Cash Flow (TTM) Free Cash Flow $-77.38m
Cash position $349.09m
EPS (TTM) EPS $-5.27
P/E forward negative
Short interest 48.08%
Show more

Is ARCA biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

ARCA biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a ARCA biopharma, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a ARCA biopharma, Inc. forecast:

Buy
100%

Financial data from ARCA biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
60% 60%
-
- -
-
-
- Selling and Administrative Expenses 16 16
133% 133%
-
- Research and Development Expense 71 71
8,919% 8,919%
-
-88 -88
1,011% 1,011%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -88 -88
998% 998%
-
Net Profit -78 -78
1,201% 1,201%
-

In millions USD.

Don't miss a Thing! We will send you all news about ARCA biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ARCA biopharma, Inc. Stock News

Neutral
GlobeNewsWire
about 8 hours ago
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of care MENLO PARK, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotech...
Neutral
GlobeNewsWire
6 days ago
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, Phase 1 initiatio...
Neutral
GlobeNewsWire
22 days ago
MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, 2025, at...
More ARCA biopharma, Inc. News

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Head office United States
CEO Lawrence Klein
Employees 28
Founded 1992
Website www.orukatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today